Prosecution Insights
Last updated: November 04, 2026
Application No. 18/277,956

PYRIDONE COMPOUNDS AND METHODS OF USE

Final Rejection §112
Filed
Aug 18, 2023
Priority
Feb 19, 2021 — provisional 63/151,334 +2 more
Examiner
WARD, PAUL V
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Exelixis Inc.
OA Round
2 (Final)
83%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
71%
With Interview

Examiner Intelligence

Grants 83% — above average
83%
Career Allowance Rate
1425 granted / 1712 resolved
+23.2% vs TC avg
Minimal -12% lift
Without
With
+-12.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
62 currently pending
Career history
1761
Total Applications
across all art units

Statute-Specific Performance

§101
5.5%
-34.5% vs TC avg
§103
20.2%
-19.8% vs TC avg
§102
18.7%
-21.3% vs TC avg
§112
42.7%
+2.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1712 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION STATUS OF THE CLAIMS: Claims 1, 4, 17, 19, 23, 26-29, 35, 37, 40, 42, and 44 are pending in this application. Claims 1, 4, 17, 19, 23, 26-29, 35, 37, 40, and 44 are allowed. Claim 42 is maintained for the reasons of record as set forth today and in the Office Action posted on June 22, 2026. Response to Arguments & Amendment Regarding Claim Rejections - 35 USC §§ 112, 1st & 2nd paragraphs Applicant’s arguments filed September 22, 2026, with respect to Claim Rejections under 35 USC §§ 112, 1st paragraph (i.e., lack of enablement) and 2nd paragraph have been fully considered and are persuasive. Thus, the rejections has been withdrawn. However, Applicant's arguments filed with respect to Claim 42 rejection under 35 USC §§ 112, 1st paragraph (i.e., lack of enablement) have been fully considered but they are not persuasive as discussed below. Response to Arguments Regarding Claim 42 Rejection under 35 USC § 112, first paragraph Applicant's arguments filed September 22, 2026, have been fully considered but they are not persuasive. Applicant contends that since claim 42 was amended to include “wherein the protein kinase is AXL, KDR, Mer or Met” and that since the disclosure provided by the specification in which assays for determining kinase activity and compound inhibition were disclosed in Tabe 2 of the specification as filed, then the claim is enabled, and thus, complies with 35 USC § 112, first paragraph enablement requirement. However, Applicant arguments are inexact and misplaced. First, Examiner will remind applicant that there are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is “undue”. These factors include but are not limited to the breadth of the claims; nature of the invention; state of the prior art; level of one of ordinary skill; level of predictability in the art; amount of direction provided by the inventor; existence of working examples; and the quantity of experimentation needed to make or use the invention based on the content of the disclosure. Claim 42 is directed to a method of treating disorders associated in modulating in vivo activity of protein kinase, wherein the protein kinase is AXL, KDR, Mer or Met. In light of this, it can be asserted that in spite of the vast expenditure of human and capital resources in recent years, there are no agents that treat all disorders, diseases or syndromes associated in modulating in vivo activity of protein kinase, wherein the protein kinase is AXL, KDR, Mer or Met. In re Hokum, 226 USPQ 353 The breadth of the instant claim 42 is seen to encompass a method for treating disorders associated in modulating in vivo activity of protein kinase, wherein the protein kinase is AXL, KDR, Mer or Met by administering to a patient in need of such treatment a therapeutically effective amount of a compound of Formulae (Ia), (Ib) and (Ic). Applicant fail to specify a particular disorder or disease. Thus, the claim is extremely broad. The nature of the invention is the treatment of disorders associated in modulating in vivo activity of protein kinase, wherein the through the use of the compounds of Formulae (Ia), (Ib) and (Ic) thereof. Currently, there are no agents that treat these diseases all inclusively. The treatment of these disorders is highly unpredictable. It is well established that “the scope of enablement varies inversely with the degree of unpredictability of the factors involved,” and physiological activity is generally considered to be an unpredictable factor. See In re Fisher, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). The applicant has not demonstrated sufficient guidance provided in the form of administration profiles, combination ratios of the active agents or reference to the same in the prior art to provide a skilled artisan with sufficient guidance to practice the instant treatment of disorders claimed. Further, the applicant discloses that an effective amount of the compound will be administered without providing any direction other than that the compounds of the invention have a high therapeutic index and follows this with a definition readily found in a basic pharmacology textbook. It should be noted that the therapeutic index of a drug in humans is almost never known and is only determined through clinical experience. There is not seen in the disclosure, sufficient evidence to support Applicant’s claims for treating these disorders with all of the compounds of Formulae (Ia), (Ib) and (Ic). A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. In re Wright, 27 USPQ2d 1510 (CAFC). The disclosure does not demonstrate sufficient evidence to support the applicant's claim to the treatment. There are not sufficient working examples or data from references of the prior art to provide a nexus between those examples and a method of treating the disorders with the claimed compound. The level of skill is that of one with a doctoral understanding of these disorder therapeutics. Applicant’s data is not convincing as to make the production and use of pharmaceutical compositions comprising the recited compounds feasible without undue and unpredictable experimentation. A great deal of experimentation is required for the method of treating disorders associated in modulating in vivo activity of protein kinase wherein the protein kinase is AXL, KDR, Mer or Met. Furthermore, direction, in the form of examples, must be shown to determine what an effective dose may be. The references submitted do not demonstrate this. Therefore, one of ordinary skill in the art would require a significant amount of experimentation in order to determine the effective dosage to treat the multitudes of different types of diseases with the claimed compound individually or in combination with other therapeutic agents. Thus, it can be safely concluded that the instant case fails to provide an enabling disclosure for the treatment of disorders associated in modulating in vivo activity of protein kinase, wherein the protein kinase is AXL, KDR, Mer or Met. Allowable Subject Matter Claims 1, 4, 17, 19, 23, 26-29, 35, 37, 40, and 44 are allowed. The compounds and process in claims 1, 4, 17, 19, 23, 26-29, 35, 37, 40, and 44 were not found to be obvious or anticipated by the prior art of record. The prior art does not teach or suggest the compounds and process substituted in the manner claimed by the Applicant. Therefore, these claims are allowed. Conclusion Claims 1, 4, 17, 19, 23, 26-29, 35, 37, 40, 42, and 44 are pending in this application. Claims 1, 4, 17, 19, 23, 26-29, 35, 37, 40, and 44 are allowed. Claim 42 is rejected THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL V WARD whose telephone number is (571)272-2909. The examiner can normally be reached M-F 9am to 5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PAUL V WARD/ Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Aug 18, 2023
Application Filed
Jun 22, 2026
Non-Final Rejection mailed — §112
Sep 22, 2026
Response Filed
Oct 01, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778953
Sodium 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate and pharmaceutical compositions thereof
4y 2m to grant Granted Nov 03, 2026
Patent 12778935
COMPOSITIONS OF BERBERINE URSODEOXYCHOLATE AND METHODS THEREOF FOR TREATING FATTY LIVER DISEASE, DIABETES AND HYPERLIPIDEMIA
4y 0m to grant Granted Nov 03, 2026
Patent 12778913
Treatment of Age-Related Macular Degeneration, Glaucoma, and Diabetic Retinopathy with N-Acetylcysteine Amide (NACA) or (2R,2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide)(DiNACA)
3y 2m to grant Granted Nov 03, 2026
Patent 12780848
[18F]A1F LABELED PSMA TARGETING MOLECULAR PROBE AND PREPARATION METHOD THEREFOR
3y 2m to grant Granted Nov 03, 2026
Patent 12773394
USE OF VALPROIC ACID FOR REDUCING POST-OPERATIVE SCARRING FOLLOWING A GLAUCOMA SURGERY
4y 4m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
83%
Grant Probability
71%
With Interview (-12.2%)
2y 4m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1712 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month